Viswanath Aditya, Fouda Sherouk, Fernandez Cornelius James, Pappachan Joseph M
School of Medicine, Leicester University, Leicester LE1 7RH, United Kingdom.
School of Health and Biomedical Sciences, Rmit University, Melbourne VIC, Australia.
World J Hepatol. 2024 Feb 27;16(2):152-163. doi: 10.4254/wjh.v16.i2.152.
The prevalence of metabolic-associated fatty liver disease (MAFLD) has increased substantially in recent years because of the global obesity pandemic. MAFLD, now recognized as the number one cause of chronic liver disease in the world, not only increases liver-related morbidity and mortality among sufferers but also worsens the complications associated with other comorbid conditions such as cardiovascular disease, type 2 diabetes mellitus, obstructive sleep apnoea, lipid disorders and sarcopenia. Understanding the interplay between MAFLD and these comorbidities is important to design optimal therapeutic strategies. Sarcopenia can be either part of the disease process that results in MAFLD (, obesity or adiposity) or a consequence of MAFLD, especially in the advanced stages such as fibrosis and cirrhosis. Sarcopenia can also worsen MAFLD by reducing exercise capacity and by the production of various muscle-related chemical factors. Therefore, it is crucial to thoroughly understand how we deal with these diseases, especially when they coexist. We explore the pathobiological interlinks between MAFLD and sarcopenia in this comprehensive clinical update review article and propose evidence-based therapeutic strategies to enhance patient care.
近年来，由于全球肥胖大流行，代谢相关脂肪性肝病（MAFLD）的患病率大幅上升。MAFLD现已被公认为全球慢性肝病的首要病因，它不仅会增加患者肝脏相关的发病率和死亡率，还会加重与其他合并症相关的并发症，如心血管疾病、2型糖尿病、阻塞性睡眠呼吸暂停、脂质紊乱和肌肉减少症。了解MAFLD与这些合并症之间的相互作用对于设计最佳治疗策略至关重要。肌肉减少症既可能是导致MAFLD（肥胖或肥胖症）的疾病过程的一部分，也可能是MAFLD的后果，尤其是在纤维化和肝硬化等晚期阶段。肌肉减少症还会通过降低运动能力和产生各种与肌肉相关的化学因子而加重MAFLD。因此，彻底了解如何应对这些疾病至关重要，尤其是当它们共存时。在这篇全面的临床最新综述文章中，我们探讨了MAFLD与肌肉减少症之间的病理生物学联系，并提出了基于证据的治疗策略以加强患者护理。
